MDT-AP-0813
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 63.84
- os_event
- false
- age_years
- 8.48
- sex
- F
- new_clusters
- C5
- umap1_2d
- 6.147441786
- umap2_2d
- 6.095889521
- umap1_3d
- 2.635149826
- umap2_3d
- 0.536046188
- umap3_3d
- -1.238029087
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.400
- ALLOGRAFT_REJECTION+0.230
- ESTROGEN_RESPONSE_LATE+0.230
- ESTROGEN_RESPONSE_EARLY+0.200
- INFLAMMATORY_RESPONSE+0.200
- APICAL_SURFACE+0.190
- MYOGENESIS+0.190
- KRAS_SIGNALING_UP+0.150
- IL2_STAT5_SIGNALING+0.140
- INTERFERON_ALPHA_RESPONSE+0.140
Top 10 suppressed
- E2F_TARGETS-0.580
- G2M_CHECKPOINT-0.560
- MITOTIC_SPINDLE-0.520
- MYC_TARGETS_V1-0.520
- DNA_REPAIR-0.430
- TGF_BETA_SIGNALING-0.430
- MYC_TARGETS_V2-0.420
- PROTEIN_SECRETION-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.410
- WNT_BETA_CATENIN_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0208 | Med | Medulloblastoma | 0.921 |
| 2 | BS_398KYV92 | Meningioma | — | 0.910 |
| 3 | TCGA-E9-A3Q9-01A-11R-A21T-07 | — | B | 0.901 |
| 4 | MDT-AP-2296 | Med | Medulloblastoma | 0.888 |
| 5 | BS_DV86M0Y7 | pilocytic astrocytoma | — | 0.887 |
| 6 | BS_5PEFNDCY | Glial-neuronal tumor NOS | — | 0.884 |
| 7 | BS_912NX4Y0 | Ganglioglioma | — | 0.881 |
| 8 | BS_Y7F9E2E9 | low-grade glioma | — | 0.880 |
| 9 | BS_0BXY0F9N | EPN | Posterior Fossa EPN | 0.880 |
| 10 | SJEPD001542_D1.RNA-Seq | EPN | Supratentorial EPN | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.140 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.030 | Idelalisib | — uncovered |